Qbic Fund | Venture Capital
Tom Smets is currently working as a Board Observer at ABSCINT and an Investment Analyst at Qbic Fund | Venture Capital. Tom previously held positions in Quality & Compliance Engineering and as a Team Lead at Ordina, where Tom worked on guiding companies towards compliance. Tom has experience as a Validation Consultant at The Janssen Pharmaceutical Companies of Johnson & Johnson and EMVO, and as a Project Engineer at Pfizer. Tom also served as Treasurer and Board Member at Vlaamse Levenstechnische kring. Tom has a postgraduate degree in Innovation and Entrepreneurship, a Master's degree in Bioscience Engineering, and a Bachelor's degree in Bioscience Engineering.
This person is not in the org chart
This person is not in any teams
Qbic Fund | Venture Capital
Qbic is a seed and early-stage venture capital fund supporting spin-offs and start-ups that valorize research from Qbic's knowledge partners. Qbic is one of the largest spin-off funds in Europe managing €190 million in resources over the different funds. Qbic I launched in 2012 and has finalized its portfolio of 18 ventures; Qbic II launched in 2017 and has a portfolio of 19 ventures, and Qbic III launched in 2022 and is currently building its portfolio.